Sofosbuvir + Velpatasvir

[SDL] Sofosbuvir & Velpatasvir Tablet, Sofosbuvir 400 mg + Velpatasvir 100 mg

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/06/2024 Direct-acting antiviral agents for treating chronic hepatitis C

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sofosbuvir 400 mg/velpatasvir 100 mg tablets

in line with its registered indications for treating chronic hepatitis C.

Funding status

[R] Sofosbuvir 400 mg/velpatasvir 100 mg tablet is recommended for inclusion on the Standard Drug List (SDL) from 1 August 2024.

[NR] Of note, glecaprevir 100 mg/pibrentasvir 40 mg tablet will be delisted from the MOH List of Subsidised Drugs with effect from 1 February 2025.

01/10/2020 Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sofosbuvir 400 mg/velpatasvir 100 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced, or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults.

• Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 1 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults.

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be used in line with the recommended treatment regimens listed in the Annex.

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be prescribed by a specialist physician (gastroenterologist, hepatologist, or infectious disease specialist) with experience in the treatment of hepatitis C.

The supplier of sofosbuvir/velpatasvir will provide retreatment with sofosbuvir/velpatasvir/voxilaprevir to patients who fail to achieve a sustained virological response with sofosbuvir/velpatasvir through their No Cure No Pay program, at no additional cost.

Subsidy status

[R] Sofosbuvir 400mg/velpatasvir 100 mg tablet and glecaprevir 100 mg/pibrentasvir 40 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indications.

[NR] MAF assistance does not apply to other direct-acting antivirals (asunaprevir, ombitasvir/paritaprevir/ritonavir+dasabuvir, sofosbuvir/ledipasvir, elbasvir/grazoprevir and daclatasvir).

01/10/2020 Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sofosbuvir 400 mg/velpatasvir 100 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults; and

• Glecaprevir 100 mg/pibrentasvir 40 mg tablet for treating genotype 2, 3, 4, 5, or 6 chronic hepatitis C infection in treatment-naïve, or pegylated interferon plus ribavirin (with or without sofosbuvir)-experienced, or sofosbuvir plus ribavirin-experienced adults.

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be used in line with the recommended treatment regimens listed in the Annex.

Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir should be prescribed by a specialist physician (gastroenterologist, hepatologist, or infectious disease specialist) with experience in treating hepatitis C.

The supplier of sofosbuvir/velpatasvir will provide retreatment with sofosbuvir/velpatasvir/voxilaprevir to patients who fail to achieve a sustained virological response with sofosbuvir/velpatasvir through their No Cure No Pay program, at no additional cost.

Subsidy status

[R] Sofosbuvir 400 mg/velpatasvir 100 mg tablet and glecaprevir 100 mg/pibrentasvir 40 mg tablet are recommended for inclusion on the Medication Assistance Fund (MAF), for the abovementioned indications.

[NR] MAF assistance does not apply to other direct-acting antivirals (sofosbuvir, sofosbuvir/velpatasvir/voxilaprevir, sofosbuvir+daclatasvir, sofosbuvir/ledipasvir and elbasvir/grazoprevir).

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration